Clémence Labetoulle is Clinical Research Associate in the neurology department of the University Hospital of Limoges (France). She studied in faculty of sciences in Limoges and clinical research in faculty of medicine in Bordeaux where she obtained the certification of clinical research assistant. She worked as clinical research assistant during 3 years in the clinical research department of Vexim, company specialized in mini-invasive vertebral consolidation in Toulouse. She joined the CHU of Limoges, as clinical research associate in pharmacology and toxicology department during 6 months. Then she integrated the neurological department in CHU Purpan in Toulouse and worked with multiple sclerosis patients as CRA, during 6 months. She came back in CHU of Limoges in 2016 and after having worked in Angiology cardiovascular surgery field, she integrated the ALS center in 2019 as a coordinator.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.